This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

This study has been withdrawn prior to enrollment.
(PI left institution)
Sponsor:
Collaborators:
Cephalon
GlaxoSmithKline
Information provided by:
Nevada Cancer Institute
ClinicalTrials.gov Identifier:
NCT01131247
First received: May 25, 2010
Last updated: July 19, 2011
Last verified: July 2011
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: No date given
  Primary Completion Date: No date given